| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/01/2009 | EP2042195A1 Polymer conjugate of combretastatin |
| 04/01/2009 | EP2042194A2 Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 04/01/2009 | EP2042191A1 Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination |
| 04/01/2009 | EP2042188A1 Pharmaceutical composition for treating or preventing hcv infection |
| 04/01/2009 | EP2042187A1 Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis |
| 04/01/2009 | EP2042184A1 Physiologically active polypeptide, polymer micelle having protein enclosed therein, and process for production of the polymer micelle |
| 04/01/2009 | EP2042182A1 Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| 04/01/2009 | EP2041178A2 Single-chain multivalent binding proteins with effector function |
| 04/01/2009 | EP2041160A2 Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy |
| 04/01/2009 | EP2041158A2 Peptide epoxyketones for proteasome inhibition |
| 04/01/2009 | EP2041141A2 Benzopyranopyrazoles |
| 04/01/2009 | EP2041140A2 Aziridinyl-epothilone compounds |
| 04/01/2009 | EP2041138A2 Pyrrolotriazine kinase inhibitors |
| 04/01/2009 | EP2041136A2 Selective antagonists of a2a adenosine receptors |
| 04/01/2009 | EP2041135A1 8-oxoadenine derivatives acting as modulators of tlr7 |
| 04/01/2009 | EP2041129A2 Human protein tyrosine phosphatase inhibitors and methods of use |
| 04/01/2009 | EP2041119A1 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof |
| 04/01/2009 | EP2041116A1 Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents |
| 04/01/2009 | EP2041107A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 04/01/2009 | EP2041102A2 Human protein tyrosine phosphatase inhibitors and methods of use |
| 04/01/2009 | EP2041071A2 Biaryl compositions and methods for modulating a kinase cascade |
| 04/01/2009 | EP2040752A2 Core-shell nanoparticles for thearapy and imaging purposes |
| 04/01/2009 | EP2040751A2 Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
| 04/01/2009 | EP2040750A2 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators |
| 04/01/2009 | EP2040748A2 Use of ppd for the adjuvantation of a nucleic acid vaccine |
| 04/01/2009 | EP2040738A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| 04/01/2009 | EP2040728A2 Fkbp-l and uses thereof |
| 04/01/2009 | EP2040725A2 Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| 04/01/2009 | EP2040719A1 Use of cells derived from adipose tissue for the preparation of an anti-tumour medicament |
| 04/01/2009 | EP2040711A2 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents |
| 04/01/2009 | EP2040705A2 Use of 2-benzoyl-imidazopyridines in therapeutics |
| 04/01/2009 | EP2040701A2 Aminoindazole urea derivatives |
| 04/01/2009 | EP2040699A2 Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
| 04/01/2009 | EP2040546A2 Tyrosine kinase inhibitors |
| 04/01/2009 | EP1835926A4 Plasmin-inhibitory therapies |
| 04/01/2009 | EP1653961A4 Inhibitors of akt activity |
| 04/01/2009 | EP1549341B1 Tissue factor targeted antibodies as anticoagulants |
| 04/01/2009 | EP1506175B1 N-substituted tricyclic 3-aminopyrazoles as pdgf receptor inhibitors |
| 04/01/2009 | EP1472375B1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 04/01/2009 | EP1456239B1 Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans |
| 04/01/2009 | EP1427825B1 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 04/01/2009 | EP1392669B1 Chromatographic separation method of paclitaxel and cephalomannin |
| 04/01/2009 | EP1349873B1 Modulation of il-2- and il-15-mediated t cell responses |
| 04/01/2009 | EP1131087B2 Alleviatation of prostate cancer symptoms |
| 04/01/2009 | EP1126828B1 Oral administration of adenosine analogs |
| 04/01/2009 | EP1119623B1 Mage-a3 peptides presented by hla class ii molecules |
| 04/01/2009 | EP1100873B1 Cancer cells from body fluids containing cells, isolation thereof and agents containing the same |
| 04/01/2009 | CN101400793A Novel cancer-associated antigen |
| 04/01/2009 | CN101400785A Method for production of T cell population |
| 04/01/2009 | CN101400690A Modulators of hypoxia inducible factor-1 and related uses |
| 04/01/2009 | CN101400681A Substituted indazole derivatives, their manufacture and use as pharmaceutical agents |
| 04/01/2009 | CN101400680A Spiroindolinone derivatives |
| 04/01/2009 | CN101400679A Spiroindolinone derivatives |
| 04/01/2009 | CN101400678A Thiophene-carboxamides useful as inhibitors of protein kinases |
| 04/01/2009 | CN101400670A Novel pyridine derivative having anti-helicobacter pylori activity |
| 04/01/2009 | CN101400658A Photoactive compounds and compositions and uses thereof |
| 04/01/2009 | CN101400656A Piperazine derivatives as farnesyl protein transferase inhibitors |
| 04/01/2009 | CN101400406A Compositions and methods of use for antibodies of Dickkopf-1 and/or -4 |
| 04/01/2009 | CN101400364A Method of preventing or reducing the risk or incidence of cancer using neural thread protein based peptides |
| 04/01/2009 | CN101400357A Method for treating oncological diseases |
| 04/01/2009 | CN101397346A Method for preparing asparagus pure polysaccharide having immunoregulation role |
| 04/01/2009 | CN101397326A Ginsenoside Rb1 containing impurity ginsenoside Rg2 |
| 04/01/2009 | CN101397302A 9-substituted homocamptothecins compounds and its use as medicaments |
| 04/01/2009 | CN101397301A Water-soluble derivates containing 10-hydroxycamptothecin and preparation method |
| 04/01/2009 | CN101397295A 2-dihydroindolemanone derivates as histone deacetylase inhibitor, preparation method and use thereof |
| 04/01/2009 | CN101397274A Novel natural imidazole formic acid derivates, preparation method and use thereof |
| 04/01/2009 | CN101397244A Anti-tumor diterpenoid isoeuphpekinensin in euphorbia perkinensis root and extraction method thereof |
| 04/01/2009 | CN101397241A Ent-abieta diterpenoid largeleaf rabdosia leaf I and J, preparation method and use thereof |
| 04/01/2009 | CN101397132A Water-soluble fullerenes derivates, composition and application thereof in preparation of medicament for inhibiting tumor growth and metastasis |
| 04/01/2009 | CN101396563A Chitose derivates using octreotide as target ligand and use thereof in medicament |
| 04/01/2009 | CN101396555A Methods and compositions for interferon therapy |
| 04/01/2009 | CN101396553A Recombined human blood vessel endothelial inhibin sustained-release injection composition |
| 04/01/2009 | CN101396489A Medicine for treating cancer |
| 04/01/2009 | CN101396432A Method for concentrating and separating flavonoids from toona sinensis leaves |
| 04/01/2009 | CN101396378A Nano gene peptides products and preparation method and use thereof |
| 04/01/2009 | CN101396373A Cinobufacini extract and preparation method thereof |
| 04/01/2009 | CN101396367A Use of marsdenia tenacissima new glycoside B in preparing medicine for treating tumor disease and preparation method thereof |
| 04/01/2009 | CN101396354A Stable taxabe compound liquid combination and preparation method and use thereof |
| 04/01/2009 | CN101396351A Drug-loaded polyelectrolyte capsules in response to phosphatase concentration and preparation method thereof |
| 04/01/2009 | CN101396347A Preparation method of recombined human blood-vessel endothelia inhibin sustained-released microsphere |
| 04/01/2009 | CN101396346A Paclitaxel lipid composite |
| 04/01/2009 | CN101396343A Paclitaxel submicron emulsion using lipid composite as middle carrier |
| 04/01/2009 | CN101396342A Anti-cancer sustained-released injection containing epothilone derivate |
| 04/01/2009 | CN101396341A Anti-cancer sustained-released agent |
| 04/01/2009 | CN101396340A Anti-cancer sustained-released injection containing epothilone derivate |
| 04/01/2009 | CN101396338A Sustained-release injection containing methotrexate and synergist thereof |
| 04/01/2009 | CN100473721C Pneumovirus NS proteins antagonising interferon (IFN) response |
| 04/01/2009 | CN100473664C Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| 04/01/2009 | CN100473661C Novel dammarane sapogenins, use thereof as anti-cancer agents, and a process for producing the same |
| 04/01/2009 | CN100473648C 1,2,4-triazole derivatives containing a sulphamate group as aromatase inhibitors |
| 04/01/2009 | CN100473644C 9-substituted minocycline compounds |
| 04/01/2009 | CN100473417C Method of modulating memory effector T-cells using CD2-binding agent, and compositions |
| 04/01/2009 | CN100473388C Extraction of effective portion of gryllotalpidae for anti-cancers and preparation thereof |
| 04/01/2009 | CN100473381C Use of epothilones in the treatment of brain diseases associated with proliferative processes |
| 04/01/2009 | CN100473376C Stabilized aqueous suspensions for parenteral administration |
| 03/31/2009 | US7511144 Reverse hydroxamic acid derivatives |
| 03/31/2009 | US7511138 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| 03/31/2009 | US7511136 Anticancer agents; antiproliferative agents; Alzheimer's disease; viricides; autoimmune diseases; central nervous system disorders |
| 03/31/2009 | US7511123 Binding to antigen; controlling concentration |
| 03/31/2009 | US7511121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |